105 related articles for article (PubMed ID: 36549117)
1. Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma.
Rishfi M; Krols S; Martens F; Bekaert SL; Sanders E; Eggermont A; De Vloed F; Goulding JR; Risseeuw M; Molenaar J; De Wilde B; Van Calenbergh S; Durinck K
Eur J Med Chem; 2023 Feb; 247():115033. PubMed ID: 36549117
[TBL] [Abstract][Full Text] [Related]
2. PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc.
Boi D; Souvalidou F; Capelli D; Polverino F; Marini G; Montanari R; Pochetti G; Tramonti A; Contestabile R; Trisciuoglio D; Carpinelli P; Ascanelli C; Lindon C; De Leo A; Saviano M; Di Santo R; Costi R; Guarguaglini G; Paiardini A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884931
[TBL] [Abstract][Full Text] [Related]
3. Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.
Felgenhauer J; Tomino L; Selich-Anderson J; Bopp E; Shah N
Neoplasia; 2018 Oct; 20(10):965-974. PubMed ID: 30153557
[TBL] [Abstract][Full Text] [Related]
4. Boolean modeling identifies Greatwall/MASTL as an important regulator in the AURKA network of neuroblastoma.
Dahlhaus M; Burkovski A; Hertwig F; Mussel C; Volland R; Fischer M; Debatin KM; Kestler HA; Beltinger C
Cancer Lett; 2016 Feb; 371(1):79-89. PubMed ID: 26616283
[TBL] [Abstract][Full Text] [Related]
5. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma.
Romain C; Paul P; Kim KW; Lee S; Qiao J; Chung DH
J Pediatr Surg; 2014 Jan; 49(1):159-65. PubMed ID: 24439602
[TBL] [Abstract][Full Text] [Related]
6. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
[TBL] [Abstract][Full Text] [Related]
7. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.
Otto T; Horn S; Brockmann M; Eilers U; Schüttrumpf L; Popov N; Kenney AM; Schulte JH; Beijersbergen R; Christiansen H; Berwanger B; Eilers M
Cancer Cell; 2009 Jan; 15(1):67-78. PubMed ID: 19111882
[TBL] [Abstract][Full Text] [Related]
8. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
[TBL] [Abstract][Full Text] [Related]
9. Selective targeting of non-centrosomal AURKA functions through use of a targeted protein degradation tool.
Wang R; Ascanelli C; Abdelbaki A; Fung A; Rasmusson T; Michaelides I; Roberts K; Lindon C
Commun Biol; 2021 May; 4(1):640. PubMed ID: 34050235
[TBL] [Abstract][Full Text] [Related]
10. A Temporal PROTAC Cocktail-Mediated Sequential Degradation of AURKA Abrogates Acute Myeloid Leukemia Stem Cells.
Liu F; Wang X; Duan J; Hou Z; Wu Z; Liu L; Lei H; Huang D; Ren Y; Wang Y; Li X; Zhuo J; Zhang Z; He B; Yan M; Yuan H; Zhang L; Yan J; Wen S; Wang Z; Liu Q
Adv Sci (Weinh); 2022 Aug; 9(22):e2104823. PubMed ID: 35652200
[TBL] [Abstract][Full Text] [Related]
11. Targeting aurora kinase A inhibits hypoxia-mediated neuroblastoma cell tumorigenesis.
Romain CV; Paul P; Lee S; Qiao J; Chung DH
Anticancer Res; 2014 May; 34(5):2269-74. PubMed ID: 24778030
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of Aurora-A and ATR kinase results in regression of
Roeschert I; Poon E; Henssen AG; Garcia HD; Gatti M; Giansanti C; Jamin Y; Ade CP; Gallant P; Schülein-Völk C; Beli P; Richards M; Rosenfeldt M; Altmeyer M; Anderson J; Eggert A; Dobbelstein M; Bayliss R; Chesler L; Büchel G; Eilers M
Nat Cancer; 2021 Mar; 2(3):312-326. PubMed ID: 33768209
[TBL] [Abstract][Full Text] [Related]
13. Aurora Kinase A inhibition enhances DNA damage and tumor cell death with
Kumar P; Koach J; Nekritz E; Mukherjee S; Braun BS; DuBois SG; Nasholm N; Haas-Kogan D; Matthay KK; Weiss WA; Gustafson C; Seo Y
Res Sq; 2024 Jan; ():. PubMed ID: 38313265
[TBL] [Abstract][Full Text] [Related]
14. MCPIP1 Exogenous Overexpression Inhibits Pathways Regulating MYCN Oncoprotein Stability in Neuroblastoma.
Boratyn E; Nowak I; Durbas M; Horwacik I; Sawicka A; Rokita H
J Cell Biochem; 2017 Jul; 118(7):1741-1755. PubMed ID: 27935099
[TBL] [Abstract][Full Text] [Related]
15. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
16. Aurora kinase A is a possible target of OSU‑03012 to destabilize MYC family proteins.
Silva A; Wang J; Lomahan S; Tran TA; Grenlin L; Suganami A; Tamura Y; Ikegaki N
Oncol Rep; 2014 Sep; 32(3):901-5. PubMed ID: 25017515
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Proteomics of Th-MYCN Transgenic Mice Reveals Aurora Kinase Inhibitor Altered Metabolic Pathways and Enhanced ACADM To Suppress Neuroblastoma Progression.
Hsieh CH; Cheung CHY; Liu YL; Hou CL; Hsu CL; Huang CT; Yang TS; Chen SF; Chen CN; Hsu WM; Huang HC; Juan HF
J Proteome Res; 2019 Nov; 18(11):3850-3866. PubMed ID: 31560547
[TBL] [Abstract][Full Text] [Related]
18. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
19. ISL1 promoted tumorigenesis and EMT via Aurora kinase A-induced activation of PI3K/AKT signaling pathway in neuroblastoma.
Li M; Sun C; Bu X; Que Y; Zhang L; Zhang Y; Zhang L; Lu S; Huang J; Zhu J; Wang J; Sun F; Zhang Y
Cell Death Dis; 2021 Jun; 12(6):620. PubMed ID: 34131100
[TBL] [Abstract][Full Text] [Related]
20. Aurora kinase A is superior to Ki67 as a prognostic indicator of survival in neuroblastoma.
Ramani P; Nash R; Rogers CA
Histopathology; 2015 Feb; 66(3):370-9. PubMed ID: 25297850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]